Sanofi, Lilly, Novo and a trio of PBMs face racketeering claims over pricey insulin drugs

Diabetes giants Sanofi, Eli Lilly and Novo Nordisk, plus a trio of pharmacy benefit managers will have to face racketeering charges over claims they systematically hiked the price of insulin drugs.

U.S. District Judge Brian Martinotti on Friday denied motions by the defendants—which also include PBM bigwigs OptumRx, Caremark and Express Scripts—to scrap claims under the Racketeer Influenced and Corrupt Organizations (RICO) Act.